Latest Breaking News On - Receptor directed therapy - Page 1 : comparemela.com

FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Novartis pharmaceuticalsUs national library of medicineDrug administrationInternational prospectivePriority reviewNew drug applicationPrescription drug user fee actBreakthrough therapyNew england journalEngland journalReceptor directed therapyCombination with socVersus soc aloneAdult male patients with

Novartis Pharma AG: Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who have been treated

United statesNew jerseyUnited kingdomSouth lanarkshireGreat britainShreeram aradhyeRichard jarvisIsabella zinckMichael meoSatoshi sugimotoNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonMary carmichael

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

France generalUnited statesNorthern irelandUnited kingdomIsabella zinckKarim fizaziFran rodriguesNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonGustave roussyAlina levchukEuropean commissionWorld health organization

Novartis receives positive CHMP opinion for Pluvicto® for

Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 .

United statesFrance generalKarim fizaziGustave roussyEuropean commissionWorld health organizationInternational prospectiveExchange commissionInnovative medicines internationalNovartis pharmaceuticalsUs national library of medicineEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useMedical oncology

Novartis Pharma AG: Novartis receives positive CHMP opinion for Pluvicto for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Phase III VISION trial showed Pluvicto plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and

France generalUnited statesIsabella zinckKarim fizaziFran rodriguesNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonGustave roussyAlina levchukEuropean commissionWorld health organizationInternational communicationsNovartis us external communications